Actually, there are many STING-activating cancer vaccines exhibiting potent antitumor activity in preclinical studies, including STINGVAX, CDN/neoantigen co-delivering nanovaccines, PC7A, and self-degradable poly(β-amino ester)s (120–123). Here, STING1 is linked to cancer.